Skip to main content
Article thumbnail
Location of Repository

Alternate Splicing of Interleukin-1 Receptor Type II (IL1R2) In Vitro Correlates with Clinical Glucocorticoid Responsiveness in Patients with AIED

By Andrea Vambutas, James DeVoti, Elliot Goldofsky, Michael Gordon, Martin Lesser and Vincent Bonagura


Autoimmune Inner Ear Disease (AIED) is poorly characterized clinically, with no definitive laboratory test. All patients suspected of having AIED are given glucocorticoids during periods of acute hearing loss, however, only half initially respond, and still fewer respond over time

Topics: Research Article
Publisher: Public Library of Science
OAI identifier:
Provided by: PubMed Central

Suggested articles


  1. (2006). Abnormal T cell activation caused by the imbalance of IL-1/IL-1R antagonist system is responsible for the development of experimental autoimmune encephalomyelitis.
  2. (2001). Activation of cell mediated immunity following immunization with pneumococcal conjugate or polysaccharide vaccine.
  3. (2008). Anakinra improves sensory deafness in a japanese patient with Muckle-Wells syndrome, possibly inhibiting the cryopyrin inflammasome.
  4. (2003). Antibodies to HSP70 in normal donors and autoimmune hearing loss patients.
  5. (2004). Autoimmune inner ear disease.
  6. (1979). Autoimmune sensorineural hearing loss.
  7. (1999). Bacterial lipopolysaccharide causes rapid shedding, followed by inhibition of mRNA expression, of the IL-1 type II receptor, with concommitant upregulation of the type I receptor and induction of incompletely spliced transcripts.
  8. (2002). Clinical and experimental studies of autoimmune inner ear disease.
  9. (1996). Cloning and characterization of an alternativly processed human type II interleukin-1 receptor mRNA.
  10. (2002). Coordinate regulation of transcription and splicing by steroid receptor coregulators.
  11. (2005). Corticosteroid response and supporting cell antibody in autoimmune hearing loss.
  12. (2005). Differential regulation of type I and type 2 interleukin-1 receptors in focal brain inflammation.
  13. (2005). Etanercept treatment for autoimmune inner ear disease: results of a pilot placebo-controlled study.
  14. (1998). Failure of elevated heat shock protein 70 antibodies to alter cochlear function in mice.
  15. (2002). Functional genomic analysis of type 2 IL-1beta decoy receptor: potential for gene therapy in human arthritis and inflammation.
  16. (2008). Functional variants in the B-cell gene BANK1 are associated with systemic lupus erythematosus.
  17. (2004). HLA-DRB1*04 and HLA-DQB1*03 association with the atrophic but not with the goitrous form of chronic autoimmune thyroiditis in a Brazilian population.
  18. (2006). Human leukocyte antigen DRB1*04 is associated with rheumatoid arthritis in Kuwaiti patients.
  19. (2005). Human leukocyte antigen-DQB1 and -DRB1 associations in patients with idiopathic sudden sensorineural hearing loss from a defined population of Northwest Spain2005.
  20. (1997). IFN-gamma and IL-10 inhibit induction of the IL-1 receptor type I and II gene expression by IL-4 and IL-13 in human monocytes.
  21. (2004). Immune mediated inner ear disease: 10-year experience.
  22. (2002). Immune-mediated hearing loss: basic mechanisms and options for therapy.
  23. (2005). Innate Immunity Contributes to Cochlear Adaptive Immune Responses.
  24. (2002). Interferon-gamma production to inner ear antigens by T cells from patients with autoimmune sensorineural hearing loss.
  25. (1993). Interleukin-1 type 2 receptor: a decoy target for IL-1 that is regulated by IL-4.
  26. (2005). Mononuclear phagocytes migrate into the murine cochlea after acoustic trauma.
  27. (2004). Murine autoimmune hearing loss mediated by CD4+ T cells specific for inner ear peptides.
  28. (2006). Proinflammatory cytokines expression in noise-induced damaged cochlea.
  29. (2006). Recopvery from deafness in a patient with Muckle-Wells syndrome treated with anakinra.
  30. (1996). Regulated expression and release of the IL-1 decoy receptor in human mononuclear phagocytes.
  31. (2003). Risk of bacterial meningitis in children with cochlear implants.
  32. (1997). Role of metalloproteases in the release of the IL-1 type 2 decoy receptor.
  33. (2005). Serial audiometry in a clinical trial of AIED treatment.
  34. (1994). Serum antibody to inner ear proteins in patients with progressive hearing loss. Correlation with disease activity and response to corticosteroid treatment.
  35. (2006). Serum heat shock protein 70 and its correlation with clinical characteristics in patients with sudden sensorineural hearing loss.
  36. (2003). Shedding of the type II IL-1 decoy receptor requires a functional aminopeptidase, aminopeptidase regulator of TNF receptor type 1 shedding.
  37. (2002). Sudden sensorineural hearing loss: supporting the immunologic theory.
  38. (1999). T cells infiltrating from the systemic circulation proliferate in the endolymphatic sac.
  39. (1996). The combination of endotoxin and dexamethasone induces type 2 interleukin I receptor (IL-1R2) in monocytes: a comparison to interleukin 1 beta (IL-1 beta) and interleukin 1 receptor antagonsist (IL-1ra).
  40. (2000). The membrane bound form of the type II IL-1 receptor accounts for inhibitiory function.
  41. (2000). The type 2 decoy receptor of IL-1 inhibits murine collagen-induced arthritis.
  42. (1994). They type II ‘‘Receptor’’ as a decoy target for interleukin 1 in polymorphnuclear leukocytes: characterization of induction by dexamethasone and ligand binding properties of the released decoy receptor.
  43. (2003). Treatment of corticosteroid-responsive autoimmune inner ear disease with methotrexate: a randomized controlled trial.
  44. (2003). Tuning of innate immunity and polarized responses by decoy receptors.

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.